Hydroxychloroquine-related retinal toxicity

Rheumatology (United Kingdom)

Volumn 55, Issue 6, 2016, Pages 957-967

  Ding, Hui Jen ^a,b,e   Denniston, Alastair K ^b,c   Rao, Vijay K ^b   Gordon, Caroline ^b,d  

^a PUTRAJAYA HOSPITAL   (Malaysia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d CITY HOSPITAL   (United Kingdom)

^e HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Erythematosus; Hydroxychloroquine; Ocular safety; Retinal toxicity; Risks; Screening modalities; Systemic lupus

Indexed keywords

HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT;

AUTOFLUORESCENCE; CORNEAL VERTICILLATA; DRUG SAFETY; ELECTRORETINOGRAPHY; EYE TOXICITY; FUNDUS AUTOFLUORESCENCE; HUMAN; HUMPHREY PERIMETER; KERATOPATHY; PERIMETRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; RISK FACTOR; SCREENING; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; UNITED KINGDOM; UNITED STATES; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; FLUORESCENCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; RETINA DISEASE; RHEUMATIC DISEASES;

ANTIRHEUMATIC AGENTS; HUMANS; HYDROXYCHLOROQUINE; OPTICAL IMAGING; RETINAL DISEASES; RHEUMATIC DISEASES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84974827126     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev357     Document Type: Review

References (95)

1. Payne JF. A postgraduate lecture on lupus erythematosus. Clin J 1894;4:223-9.
2. Martenstein H. Subacute lupus erythematosus and tubercular cervical adenopathy. Treatment with plasmochin. Z Hautkr 1928;27:248-9.
3. Davidson AM, Birt AR. Quinine bisulfate as a desensitizing agent in treatment of lupus erythematosus. Arch Derm Syphilol 1938;37:247-53.
4. Wallace DJ. The history of antimalarials. Lupus 1996;5(Suppl 1):S2-3.
5. Page F. Treatment of lupus erythematosus with mepacrine. Lancet 1951;2:755-8.
6. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
7. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006;12:294-304.
8. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011;7:718-29.
9. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991;324:150-4.
10. Fessler BJ, Alarcón GS, McGwin G Jr et al. LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
11. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366-70.
12. Alarcón GS, McGwin G, Bertoli AM et al, for the LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72.
13. Hanly JG, Urowitz MB, Su L et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis 2012;71:1502-9.
14. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996;5(Suppl 1):S16-22.
15. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996;25:191-3.
16. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989;27:81-779.
17. Raines MF, Bhargava SK, Rosen ES. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 1989;30:1726-31.
18. Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978;17:1158-75.
19. Sundelin SP, Terman A. Different elements of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 2002;100:481-9.
20. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983;75:25-34.
21. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008;23:201-9.
22. Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol 2012;6:377-83.
23. Costedoat-Chalumeau N, Amoura Z, Hulot JS et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007;66:821-4.
24. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013;27:329-40.
25. Koneru S, Kocharla L, Higgins GC et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 2008;14:195-201.
26. Ting TV, Kudalkar D, Nelson S et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012;39:174-9.
27. Rodriguez-Padilla JA, Hedges TR III, Monson B et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 2007;125:775-80.
28. Stepien KE, Han DP, Schell J et al. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. Trans Am Ophthalmol Soc 2009;107:28-33.
29. Chen E, Brown DM, Benz MS et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the flying saucer sign). Clin Ophthalmol 2010;4:1151-8.
30. Omri S, Omri B, Savoldelli M et al. The outer limiting membrane (OLM) revisited: clinical implications. Clin Ophthalmol 2010;4:183-95.
31. Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. Eye 2011;25:1535-45.
32. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 2006;47:3531-8.
33. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 2007;143:801-9.
34. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82.
35. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415-22.
36. Vu BL, Easterbrook M, Hovis JK. Detection of color vision defects in chloroquine retinopathy. Ophthalmology 1999;106:1799-803.
37. Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 1983;75:35-9.
38. Thorne JE, Maguire AM. Retinopathy after long term, standard doses of hydroxychloroquine. Br J Ophthalmol 1999;83:1194.
39. Crews SJ. Chloroquine retinopathy with recovery in early stages. Lancet 1964;284:436-8.
40. Tobin DR, Krohel G, Rynes RI. Hydroxychloroquine. Seven-year experience. Arch Ophthalmol 1982;100:81-3.
41. Turgut B, Turkcuoglu P, Serdar Koca S, Aydemir O. Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol 2009;28:607-9.
42. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol 2004;122:973-81.
43. Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: review of mfERG ring ratios in Plaquenil toxicity. Doc Ophthalmol 2009;118:29-36.
44. Moschos MN, Moschos MM, Apostolopoulos M et al. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc Ophthalmol 2004;108:47-53.
45. Lai TY, Chan WM, Li H, Lai RY, Lam DS. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005;140:794-807.
46. Mititelu M, Wong BJ, Brenner M et al. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol 2013;131:1187-97.
47. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991;112:528-34
48. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 2011;129:30-9.
49. Vavvas D, Huynh N, Pasquale L, Berson EL. Progressive hydroxychloroquine toxicity mimicking low-tension glaucoma after discontinuation of the drug. Acta Ophthalmol 2010;88:156-7.
50. Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report. Chang Gung Med J 2001;24:329-34.
51. Lally DR, Maler S, Bussel II et al. Evaluation of spectraldomain optical coherence tomography in patients with hydroxychloroquine retinal toxicity after drug cessation [abstract]. Invest Ophthalmol Vis Sci 2014;55:E-Abstract 4879.
52. Salu P, Uvijls A, van den Brande P, Leroy BP. Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. Doc Ophthalmol 2010;120:251-64.
53. Reed H, Karlinsky W. Delayed onset of chloroquine retinopathy. Can Med Assoc J 1967;97:1408-11.
54. Levy GD, Munz SJ, Paschal J et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40:1482-6.
55. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2010;62:775-84.
56. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983; 75:40-5.
57. Wang C, Fortin PR, Li Y et al. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol 1999;26:808-15.
58. Mavrikakis I, Sfikakis PP, Mavrikakis E et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003;110:1321-6.
59. Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt's disease? Am J Ophthalmol 2001;131:761-6
60. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996;55:187-9.
61. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol 1993;25:385-8.
62. Bienfang D, Coblyn JS, Liang MH, Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 2000;27:2703-6.
63. Rüther K, Foerster J, Berndt S, Schroeter J. [Chloroquine/ hydroxychloroquine: variability of retinotoxic cumulative doses]. [Article in German] Ophthalmologe 2007;104:875-9.
64. Bergholz R, Schroeter J, Rüther K. Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol 2010;94:1637-42.
65. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104:139-44.
66. Costedoat-Chalumeau N, Amoura Z, Hulot JS et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90.
67. Lee JY, Luc S, Greenblatt DJ, Kalish R, McAlindon TE. Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. Lupus 2013;22:541-2.
68. Tailor R, Elaraoud I, Good P, Hope-Ross M, Scott RA. A case of severe hydroxychloroquine-induced retinal toxicity in a patient with recent onset of renal impairment: a review of the literature on the use of hydroxychloroquine in renal impairment. Case Rep Ophthalmol Med 2012;Article ID182747.
69. Payne JF, Hubbard GB III, Aaberg TM Sr, Yan J. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol 2011;95:245-50.
70. Stelton CR, Connors DB, Walia SS, Walia HS. Hydroxychloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol 2013;32:895-8.
71. Marmor MF, Chien FY, Johnson MW. Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy. JAMA Ophthalmol 2013;131:476-80.
72. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 2012;130:461-9.
73. Martínez-Costa L, Ibanez MV, Murcia-Bello C et al. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. Can J Ophthalmol 2013:48;400-5.
74. Bourke B, Jones S, Rajammal AK, Silman A, Smith R. Hydroxychloroquine and Ocular Toxicity Recommendations on Screening. The Royal College of Ophthalmologists in association with The British Society for Rheumatology and the British Association of Dermatologists, 2009. https://www.rcophth.ac.uk/?s=hydroxychloroquine (14 September 2015, date last accessed).
75. Marmor MF, Melles RB. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology 2014;121:1257-62.
76. Lai TY, Ngai JW, Chan WM, Lam DS. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc Ophthalmol 2006;112:177-87.
77. Elder M, Rahman AM, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol 2006;124:1729-33.
78. Marmor MF. Efficient and effective screening for hydroxychloroquine toxicity. Am J Ophthalmol 2013;155:413-4.
79. Huang D, Swanson EA, Lin CP et al. Optical coherence tomography. Science 1991;254:1178-81.
80. Pasadhika S, Fishman GA, Choi D, Shahidi M. Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. Eye 2010;24:756-62; quiz 763.
81. Ulviye Y, Betul T, Nur TH, Selda C. Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine. Indian J Ophthalmol 2013;61:168-71.
82. Delori FC, Dorey CK, Staurenghi G et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718-29.
83. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a review. Eye 1995;9:763-71.
84. Okubo A, Rosa RH Jr, Bunce CV et al. The relationships of age changes in retinal pigment epithelium and Bruch's membrane. Invest Ophthalmol Vis Sci 1999;40:443-9.
85. Holz FG, Bellman C, Staudt S, Schütt F, Völcker HE. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001;42:1051-6.
86. Sutter EE, Tran D. The field topography of ERG components in man. I. The photopic luminance response. Vision Res 1992;32:433-66.
87. Kellner S, Weinitz S, Kellner U. Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and nearinfrared autofluorescence. Br J Ophthalmol 2009;93:1444-7.
88. Gilbert ME, Savino PJ. Missing the bull's eye. Surv Ophthalmol 2007;52:440-2.
89. Cukras CA, Huynh N, Vitale S et al. Assessment of subjective and objective screening parameters for the detection of functional hydroxychloroquine toxicity [abstract]. Invest Ophthalmol Vis Sci 2014;55:E-Abstract 4881.
90. So SC, Hedges TR, Schuman JS, Quireza ML. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. Ophthal Surg Lasers Imaging 2003;34:251-8.
91. Fraenkel L, Felson DT. Rheumatologists' attitudes toward routine screening for hydroxychloroquine retinopathy. J Rheumatol 2001;28:1218-21.
92. Samanta A, Goh L, Bawendi A. Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Rheumatology 2004;43:346-8.
93. Semmer AE, Lee MS, Harrison AR, Olsen TW. Hydroxychloroquine retinopathy screening. Br J Ophthalmol 2008;92;1653-5.
94. Browning DJ. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol 2013;155:418-28.e1.
95. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 2014;132:1105-12.